Rob McMaster poured his heart and soul into his father's business for 38 years, but at 54 was concerned that he lacked a successor. Intent on early succession planning, Rob established a formal Employee Share Ownership Plan to transfer ownership of his company to his employees. Then the unthinkable happened: Rob was struck with severe and debilitating health challenges just as the economy faltered and manufacturing industries were struggling. When his fledgling employee ownership plan fail...

The analytical approach of standard health economics has so far failed to sufficiently account for the nature of care. This has important ramifications for the analysis and valuation of care, and therefore for the pattern of health and medical care provision. This book sets out an alternative approach, which places care at the center of an economics of health, showing how essential it is that care is appropriately recognized in policy as a means of enhancing the dignity of the individual.

This book seeks to advance social economic analysis, economic methodology, and the history of economic thought in the context of twenty-first-century scholarship and socio-economic concerns. Bringing together carefully selected chapters by leading scholars it examines the central contributions that John Davis has made to various areas of scholarship.In recent decades, criticisms of mainstream economics have rekindled interest in a number of areas of scholarly inquiry that were freq...

‘Bad Science’ hilariously exposed the tricks that quacks and journalists use to distort science, becoming a 400,000 copy bestseller. Now Ben Goldacre puts the $600bn global pharmaceutical industry under the microscope. What he reveals is a fascinating, terrifying mess.Doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce u...

The New York Times Science Bestseller from Robert Wachter, Modern Healthcare’s #1 Most Influential Physician-Executive in the USWhile modern medicine produces miracles, it also delivers care that is too often unsafe, unreliable, unsatisfying, and impossibly expensive. For the past few decades, technology has been touted as the cure for all of healthcare’s ills.But medicine stubbornly resisted computerization – until now. Over the past five...

Even for highly qualified candidates, becoming a Medical Science Liaison is a challenging endeavor! It's nearly impossible to achieve on your own without the proper preparation and guidance... The Medical Science Liaison Career Guide: How to Break into Your First Role will show you, step by step, how to search for, apply, and interview for your first MSL role. The book reveals strategies for standing apart from the competition, what hiring managers look for when considering candidates, and...

“Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years.” — John Lescroart, New York Times bestselling author of DamageProcrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue—and still does. In 2012, world famous...

From the award-winning author of Medical Apartheid, an exposé of the rush to own and exploit the raw materials of life—including yours.Think your body is your own to control and dispose of as you wish? Think again. The United States Patent Office has granted at least 40,000 patents on genes controlling the most basic processes of human life, and more are pending. If you undergo surgery in many hospitals you must sign away ownership rights to your excised t...

In 1950, a diagnosis of cancer was all but a death sentence. Mortality rates only got worse, and as late as 1986, an article in the New England Journal of Medicine lamented: "We are losing the war against cancer." Cancer is one of humankind's oldest and most persistent enemies; it has been called the existential disease.But we are now entering a new, and more positive, phase in this long campaign. While cancer has not been cured -- and a cure may elude us for a long time y...

The explosive story of the discovery and development of psychiatric medications, as well as the science and the people behind their invention, told by a riveting writer and psychologist who shares her own experience with the highs and lows of psychiatric drugs.Although one in five Americans now takes at least one psychotropic drug, the fact remains that nearly seventy years after doctors first began prescribing them, not even their creators understand exactly how o...

Written by John Lidstone and Janice MacLennan, the second edition of Marketing Planning for the Pharmaceutical Industry became accepted as the bible for the industry. In this new companion book Janice MacLennan picks up two of the themes touched on in Marketing Planning - market segmentation and branding, and the inter-relationship between these two - and with this book makes them key topics for discussion. Brand Planning for the Pharmaceutical Industry begins by exploring what branding is...

How the FDA became the world's most powerful regulatory agencyThe U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints...